Still a product for human consumption making claims that it is a viable treatment for COVID under the emergency provisions for fast tracking.
If the agency concerned in India is not satisfied that the claims are proven, then they do have the right to ask for more testing. The size of the company should make no difference.
The fact that extra testing has been requested may not mean that much or it could be a significant lack of validation for the drug. I don't know which scenario is at play here but, if I was still a shareholder, it would make me see this as a red flag.
MXC Price at posting:
2.3¢ Sentiment: None Disclosure: Not Held
